No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:24.113Z. Latest historical point 2022-03-28. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Acumen Pharmaceuticals, Inc. (ABOS) stock was $2.13 as of Oct 5, 2026, 4:00 PM EDT, up 4.41% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +23.0% · 3-year avg -21.9%/yr · 5-year avg -32.6%/yr
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease.
Biotechnology · Newton, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.43
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.45
vs Estimate
$-0.41
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ABOS | $153.84M | $2.13 | +4.41% | +23.00% | -32.60% | N/A | N/A |
| 2AVXL | $152.45M | $1.65 | -9.62% | -83.29% | -37.74% | -7.93% | vs ABOS |
| 3CRDL | $152.16M | $1.32 | -6.38% | +23.24% | -18.36% | N/A | vs ABOS |
| 4CDXS | $149.51M | $1.39 | +2.21% | -45.12% | -44.64% | -11.05% | vs ABOS |
| 5INGN | $160.82M | $5.94 | -0.50% | -31.21% | -32.83% | -20.74% | vs ABOS |
| 6IMRX | $146.66M | $4.04 | -0.74% | -33.09% | -32.77% | N/A | vs ABOS |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 5 analysts
Average Price Target
$7.60
+256.8% upside
Low
$5.00
Current
$2.13
High
$10.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.40 | $-0.38 | $-0.36 | 2 |
| Quarter ending Dec 2026 | $-0.36 | $-0.36 | $-0.36 | 2 |
| Quarter ending Mar 2027 | $-0.30 | $-0.30 | $-0.30 | 1 |
| Quarter ending Jun 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.64 | $-1.53 | $-1.45 | 3 |
| FY 2027 | $-1.93 | $-1.48 | $-1.22 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
